Unity Biotechnology Inc (NAS:UBX)
$ 0.999 -0.036 (-3.48%) Market Cap: 16.83 Mil Enterprise Value: 9.10 Mil PE Ratio: 0 PB Ratio: 1.19 GF Score: 32/100

UNITY Biotechnology Inc At KOL Webinar Call Transcript

Nov 09, 2021 / 01:00PM GMT
Release Date Price: $25.7 (+8.90%)
Tara Sobierajski

Good morning, and welcome to the Unity Biotechnology KOL webinar and update to the lead program, UBX1325. (Operator Instructions) As a reminder, this call is being recorded, and a replay will be made available on the Unity Biotechnology website following the conclusion of the event. I'd now like to turn the call over to Lynne Sullivan, CFO and Head of Corporate Development at Unity Biotechnology. Please go ahead, Lynne.

Lynne Marie Sullivan
Unity Biotechnology, Inc. - CFO & Head of Corporate Development

Good morning. Thank you for joining Unity Biotechnology's conference call this morning to discuss the 24-week data results from our Phase I single ascending dose study of UBX1325. We will also be sharing 12-week data from an additional cohort of 7 AMD patients dosed at 10 micrograms.

With us on today's call is Dr. Robert Bhisitkul, Professor of Ophthalmology and Director of the Retina Fellowship at the University of California San Francisco; and Dr. Arshad Khanani, Managing Partner and Director of Clinical Research at Sierra Eye

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot